Diversified Trust Co Increases Stake in Regeneron Pharmaceuticals

Diversified Trust Co has recently announced a significant increase in its holdings of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). According to reports from Holdings Channel.com, the firm raised its stake in the biopharmaceutical company by an impressive 93.0% during the fourth quarter of the previous year.

Following this acquisition, Diversified Trust Co now owns a total of 2,330 shares of Regeneron Pharmaceuticals. This includes an additional purchase of 1,123 shares made during the fourth quarter. The total value of Diversified Trust Co’s holdings in Regeneron Pharmaceuticals is estimated at approximately $1,660,000 based on the firm's most recent SEC filing.

In addition to Diversified Trust Co, several other large investors have also made adjustments to their positions in Regeneron Pharmaceuticals in recent months. International Assets Investment Management LLC significantly increased its stake by an astounding 86,013.3% during the third quarter. After acquiring an additional 879,916 shares, the firm now holds 880,939 shares, valued at around $926,078,000.

Moreover, Worldquant Millennium Advisors LLC has entered into the Regeneron Pharmaceuticals market with a new stake valued at approximately $127,489,000 during the same period. Icon Wealth Advisors LLC has also made a substantial increase by raising its position in the company by 18,342.0%, now owning 75,981 shares valued at $79,874,000 after purchasing an additional 75,569 shares.

State Street Corp is yet another institutional investor that has contributed to the growing interest in Regeneron Pharmaceuticals. The firm increased its holdings by 1.3%, currently owning 4,902,404 shares worth about $5,153,603,000 after adding 61,277 additional shares in the last quarter. Massachusetts Financial Services Co. MA has also grown its ownership by 12.4%, now holding 540,293 shares valued at approximately $567,864,000 after an increase of 59,769 shares.

The interest from institutional investors is noteworthy, with 83.31% of Regeneron Pharmaceuticals’ stock currently held by institutional investors and hedge funds.

Wall Street Perspective on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals has not only garnered the attention of investors but has also been featured in various research reports by Wall Street analysts. Recently, StockNews.com downgraded the company's shares from a “strong-buy” rating to a “buy” rating in a report issued on November 4th. Wells Fargo & Company lowered their price target for the stock from $1,200.00 to $1,050.00 while maintaining an “overweight” rating.

Citi Research has also started coverage on Regeneron Pharmaceuticals, giving it a “neutral” rating along with a price objective of $895.00 in a research note published on November 14th. In a report released on November 1st, Piper Sandler cut their target price from $1,242.00 to $1,195.00, still rating the stock as “overweight.” Similarly, Morgan Stanley reported a decrease in their price target from $1,235.00 to $1,184.00, also maintaining an “overweight” rating.

Currently, the consensus among analysts shows one rating of sell, six hold ratings, sixteen buy ratings, and one strong buy rating for Regeneron Pharmaceuticals. According to MarketBeat data, the firm holds a consensus rating of “Moderate Buy” with an average price target of $1,044.48.

Regeneron Pharmaceuticals' Stock Performance

As of the latest market session, Regeneron Pharmaceuticals shares opened at $733.59. The company exhibits a 50-day moving average price of $756.46 and a 200-day moving average price of $966.75. Over the past year, Regeneron has seen stock values range from a low of $693.00 to a high of $1,211.20.

Financial fundamentals reflect a strong position with a quick ratio of 4.46, a current ratio of 5.28, and a low debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals boasts a market capitalization of $80.61 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 2.19, and a beta of 0.10.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is involved in the research, development, manufacturing, and commercialization of innovative medicines aimed at addressing a wide variety of medical conditions worldwide. Among its portfolio of products is EYLEA, which is used for the treatment of conditions such as wet age-related macular degeneration and diabetic macular edema, as well as other ocular conditions.

investment, pharmaceuticals, shares